Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenetic Biosciences (XBIO) FCF Margin (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed FCF Margin for 6 consecutive years, with 64.1% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 1064.0% year-over-year to 64.1%, compared with a TTM value of 95.07% through Sep 2025, up 2130.0%, and an annual FY2024 reading of 112.69%, up 4929.0% over the prior year.
  • FCF Margin was 64.1% for Q3 2025 at Xenetic Biosciences, up from 65.07% in the prior quarter.
  • Across five years, FCF Margin topped out at 64.1% in Q3 2025 and bottomed at 226.96% in Q1 2024.
  • Average FCF Margin over 3 years is 129.66%, with a median of 118.02% recorded in 2023.
  • Peak annual rise in FCF Margin hit 12266bps in 2024, while the deepest fall reached -4499bps in 2024.
  • Year by year, FCF Margin stood at 118.02% in 2023, then increased by 12bps to 103.88% in 2024, then surged by 38bps to 64.1% in 2025.
  • Business Quant data shows FCF Margin for XBIO at 64.1% in Q3 2025, 65.07% in Q2 2025, and 168.88% in Q1 2025.